• 3-Bromopyruvate and Cetuximab: Overcoming CRC Resistance via

  2026-05-06

  This study demonstrates that co-treatment with 3-bromopyruvate and cetuximab can overcome resistance in colorectal cancer cells by engaging autophagy-dependent ferroptosis and apoptosis pathways. The findings highlight mechanistic insights into FOXO3a signaling and suggest potential routes to enhance the efficacy of targeted therapies for resistant cancer models.

• TRPV1 Modulation Alters Immune Response in Metastatic Cancer

  2026-05-05

  This study investigates how pharmacological activation of TRPV1 channels influences immune cell cytokine profiles in mice bearing metastatic breast carcinoma. The research reveals context-dependent, and at times paradoxical, effects of TRPV1 agonists on inflammatory responses—highlighting the need for careful evaluation of TRPV1-targeted therapies in cancer-associated inflammation.

• Oltipraz: Nrf2 Pathway Activation for Chemopreventive Resear

  2026-05-05

  Oltipraz, a potent Nrf2 pathway activator, is a gold-standard tool for chemoprevention studies, enabling robust induction of phase II detoxifying enzymes in cellular models. This article decodes experimental best practices, troubleshooting, and translational insights for leveraging Oltipraz in advanced workflows focused on carcinogen detoxification and liver disease research.

• Gap26 Connexin 43 Mimetic Peptide: Mechanism, Evidence & Use

  2026-05-04

  Gap26 is a selective connexin 43 mimetic peptide that blocks gap junction communication by inhibiting connexin 43 hemichannels, crucial for studies in calcium signaling and ATP release. Peer-reviewed studies validate its efficacy in modulating neurobiological and vascular smooth muscle pathways.

• Calcein AM/PI Staining Kit: Precision in Mammalian Cell Viab

  2026-05-04

  Explore how the Calcein AM/PI Live-Dead Cell Staining Kit I delivers next-generation precision in mammalian cell viability assays. This article unveils advanced scientific insight and practical guidance, uniquely integrating biomaterial-driven research with robust fluorescence detection.

• Selective Inhibition of SARS-CoV-2 3CLpro by Merbromin: Mech

  2026-05-03

  This article reviews a high-throughput screening study identifying Merbromin as a selective mixed-type inhibitor of the SARS-CoV-2 3-chymotrypsin-like protease (3CLpro). The research highlights Merbromin’s specificity, sparing major serine and cysteine proteases such as Proteinase K, and provides a mechanistic basis for future antiviral drug design.

• Cyclophosphamide: Applied Protocols for Cancer Research Succ

  2026-05-02

  Cyclophosphamide, supplied by APExBIO, is a gold-standard alkylating chemotherapeutic agent that enables precise apoptosis induction and immune modulation in cancer and transplantation research. This guide delivers actionable workflows, troubleshooting strategies, and advanced use-cases to maximize reproducibility and data quality in your laboratory.

• Synthetic Lethality via Mcl-1 Super-Enhancer and BCL-XL Inhi

  2026-05-01

  This study demonstrates that epigenetic suppression of Mcl-1, achieved through super-enhancer targeting, is synthetically lethal when combined with BCL-XL/BCL-2 inhibition in glioblastoma models. The findings reveal a potent apoptosis induction strategy in therapy-resistant GBM, providing a mechanistic basis for dual-targeted interventions.

• Clathrin-Mediated Entry of GCRV: Insights from Inhibitor Pro

  2026-05-01

  Wang et al. (2018) provided a rigorous pharmacological inhibitor analysis demonstrating that genotype III grass carp reovirus (GCRV104) enters host cells via clathrin-mediated, dynamin- and pH-dependent endocytosis. Their findings refine mechanistic models of viral entry in aquatic virology and clarify the role of cytoskeletal disruption agents, including Latrunculin B, in this context.

• Cefodizime: Applied Workflows for Third-Generation Cephalosp

  2026-04-30

  Cefodizime, a third-generation cephalosporin antibiotic, delivers robust broad-spectrum antibacterial and immunomodulatory activity for advanced microbiology workflows. This article details optimized experimental protocols, troubleshooting, and comparative advantages, empowering researchers to leverage APExBIO’s high-quality Cefodizime for reliable infectious disease modeling and resistance studies.

• Applied Use-Cases of Probenecid in MDR and Neuroprotection R

  2026-04-30

  Probenecid (4-(dipropylsulfamoyl)benzoic acid) from APExBIO empowers multidrug resistance reversal and neuroprotection with unrivaled versatility. Integrating precise transporter inhibition, it unlocks new experimental strategies across oncology and neuroscience, surpassing conventional reagents.

• XPO1 Inhibition by Eltanexor Reduces Colorectal Tumorigenesi

  2026-04-29

  This study demonstrates that Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, effectively reduces colorectal cancer tumor burden by modulating the Wnt/β-catenin signaling pathway. The findings establish nuclear export inhibition as a promising chemopreventive approach in genetically predisposed colorectal cancer models.

• A23187, Free Acid: Calcium Ionophore for Intracellular Ca2+

  2026-04-29

  A23187, free acid is a well-characterized calcium ionophore used to elevate intracellular Ca2+ and dissect calcium-dependent signaling in vitro. It enables precise, reproducible modulation of cell signaling pathways including phosphoinositide hydrolysis and apoptosis induction via mitochondrial permeability. APExBIO’s A23187, free acid (B6646) sets a benchmark for experimental reliability in cell signaling and apoptosis studies.

• HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody: Technic

  2026-04-28

  HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody enables sensitive, specific fluorescent detection of rabbit primary antibodies, addressing the need for robust signal amplification in immunoassays. It is best employed in immunofluorescence, immunohistochemistry, and flow cytometry workflows where high specificity and minimal cross-reactivity are required. Not recommended for non-rabbit primary antibodies or protocols incompatible with sodium azide.

• Firefly Luciferase mRNA: 5-moUTP Reporter Assays Optimized

  2026-04-28

  Leverage 5-moUTP-modified Firefly Luciferase mRNA for high-sensitivity bioluminescent reporting with reduced innate immune activation and robust translation efficiency. This guide details practical workflows, troubleshooting strategies, and advanced assay design informed by cutting-edge RNA delivery research.

15616 records 1/1042 page Next 12345 下5页 Last page